Jefferies (NYSE:JEF) analyst David Windley maintained a Buy rating on Syneos Health (NASDAQ:SYNH) Inc on Monday, setting a price target of $105, which is approximately 21.95% above the present share price of $86.1.
Windley expects Syneos Health Inc to post earnings per share (EPS) of $0.40 for the fourth quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Syneos Health, with an average price target of $102.57.
The analysts price targets range from a high of $115 to a low of $93.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $1.28 billion and a net profit of $87.65 million. The company's market cap is $8.91 billion.
According to TipRanks.com, Jefferies analyst David Windley is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.6% and a 74.94% success rate.
Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded on August 13, 2010 and is headquartered in Morrisville, NC.